This article has been updated with information and quotes from Myriad Genetics' Q2 earnings call. 

NEW YORK (GenomeWeb) – Myriad Genetics reported after the close of the market on Tuesday that its second quarter revenues in fiscal 2017 grew 2 percent, beating Wall Street expectations.

For the three months ended Dec. 31, the firm reported total revenues of $196.5 million, compared to $193.3 million in Q2 2016, and beating the consensus Wall Street estimate of $189.7 million.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.